Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Neoadjuvant Carboplatin for Triple-Negative Breast Cancer
This phase III trial evaluated the addition of carboplatin to neoadjuvant chemotherapy in triple-negative breast cancer. The addition improved overall survival, particularly in pre
New Reference: Nirogacestat for Desmoid Tumors
Long-term treatment with nirogacestat resulted in an objective response rate of 45.7%. Safety findings showed a decrease in the incidence and severity of treatment-emergent adverse
New Reference: Darolutamide for Non-Metastatic Castration Resistant Prostate Cancer
In this phase 3 trial, darolutamide significantly prolonged metastasis-free survival in men with nonmetastatic, castration-resistant prostate cancer compared to placebo, reducing t
New Reference: Pazopanib for Extrapancreatic Neuroendocrine Tumors
Pazopanib demonstrated activity in prolonging progression-free survival for advanced extrapancreatic neuroendocrine tumors. However, it was associated with an increased rate of sev
New Reference: Lenvatinib – Everolimus for Metastatic Clear Cell RCC
Lenvatinib plus everolimus prolonged progression-free survival compared to cabozantinib in patients with metastatic clear cell renal cell carcinoma that progressed on prior PD-1 in
New Reference: Enzalutamide in Biochemically Recurrent Prostate Cancer
The trial showed that enzalutamide plus leuprolide significantly improved overall survival compared to leuprolide alone in patients with high-risk biochemically recurrent prostate
New Reference: Revumenib for Rel/Ref KMT2A-Rearranged AML
The AUGMENT-101 study showed that revumenib led to high response rates in relapsed or refractory KMT2A-rearranged acute leukemia. Patients had an overall response rate of 63.2% wit
New Reference: Belantamab for Multiple Myeloma
BVd therapy significantly prolonged progression-free survival compared to DVd in patients with relapsed or refractory multiple myeloma. It was associated with a higher rate of comp
New Indication: Revumenib for Rel/Ref NPM1-Mutated AML
In this study, revumenib exhibited a promising overall response rate of 46.9% in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The median overall surviv
